Originally published In Press as doi:10.1074/jbc.M206974200 on September 11, 2002
J. Biol. Chem., Vol. 277, Issue 49, 47524-47532, December 6, 2002
A Subset of Plasmodium falciparum SERA Genes Are
Expressed and Appear to Play an Important Role in the Erythrocytic
Cycle*
Susanne K.
Miller
,
Robert T.
Good,
Damien R.
Drew§,
Mauro
Delorenzi,
Paul R.
Sanders¶,
Anthony N.
Hodder,
Terence P.
Speed,
Alan F.
Cowman
,
Tania F.
de Koning-Ward**, and
Brendan S.
Crabb
From the Walter and Eliza Hall Institute of Medical Research,
Melbourne, Victoria 3050, Australia
Received for publication, July 12, 2002, and in revised form, August 22, 2002
 |
ABSTRACT |
The Plasmodium
falciparum serine repeat antigen (SERA) has shown considerable
promise as a blood stage vaccine for the control of malaria. A related
protein, SERPH, has also been described in P. falciparum.
Whereas their biological role remains unknown, both proteins possess
papain-like protease domains that may provide attractive targets for
therapeutic intervention. Genomic sequencing has recently shown that
SERA and SERPH are the fifth and sixth genes,
respectively, in a cluster of eight SERA homologues present on chromosome 2. In this paper, the expression and functional relevance
of these eight genes and of a ninth SERA homologue found on
chromosome 9 were examined in blood stage parasites. Using reverse
transcriptase-PCR and microarray approaches, we demonstrate that
whereas mRNA to all nine SERA genes is synthesized late
in the erythrocytic cycle, it is those genes in the central
region of the chromosome 2 cluster that are substantially up-regulated at this time. Using antibodies specific to each SERA, it was apparent that SERA4 to -6, and possibly also SERA9, are synthesized in blood
stage parasites. The reactivity of antibodies from malaria-immune individuals with the SERA recombinant proteins suggested that SERA2 and
SERA3 are also expressed at least in some parasite populations. To
examine whether SERA genes are essential to blood stage
growth, each of the eight chromosome 2 SERA genes was
targeted for disruption. Whereas genes at the periphery of the cluster
were mostly dispensable (SERA2 and -3 and
SERA7 and -8), those in the central region
(SERA4 to -6) could not be disrupted. The
inability to disrupt SERA4, -5, and
-6 is consistent with their apparent dominant expression and implies an important role for these genes in maintenance of the
erythrocytic cycle.
 |
INTRODUCTION |
Malaria remains one of the most devastating diseases of mankind.
It has been estimated that there are as many as 500 million clinical
cases of malaria each year including 1-2 million deaths. The emergence
of widespread drug-resistant parasites and insecticide-resistant vectors has intensified the need for novel drug target strategies and
an effective vaccine. One molecule that has potential to serve both as
a vaccine and a drug target to control Plasmodium
falciparum, the most important cause of human malaria, is the
serine repeat antigen
(SERA),1 also known as serine
stretch protein (SERP) or P126 (1-3). SERA, which is produced
in large amounts late in the blood stage cycle, is the target of
protective immune responses and possesses a domain that may function as
a protease (4-10).
P. falciparum SERA/SERP is synthesized as a 113-126-kDa
precursor protein and is localized to the parasitophorous vacuole (1,
2, 11). Synchronous with merozoite release, the precursor is processed
into N-terminal 47-kDa, centrally located 56-kDa, and C-terminal 18-kDa
fragments. The 47- and 18-kDa fragments remain linked by a disulfide
bond(s), whereas the 56-kDa domain undergoes further processing to a
50-kDa species in a manner that is inhibited by leupeptin and E64 (1,
12, 11, 13). The covalently associated N- and C-terminal fragments
appear to be associated with the merozoite surface, whereas the central
50- and 6-kDa species are shed upon schizont rupture
(14).2 This central fragment
of SERA shows a high degree of homology to the papain family of
cysteine proteases (6, 7); however, it is not yet known if SERA
possesses proteolytic activity.
SERA is well recognized as a vaccine candidate antigen (see Ref. 15 for
a review). Recombinant proteins derived from the N-terminal 47-kDa
domain are highly immunogenic and elicit antibodies that inhibit
erythrocyte invasion and parasite replication in vitro (14,
16-18). In vivo studies using rodent and primate models demonstrated that the 47-kDa domain conferred significant protection from parasite challenge (19-22).
A gene showing strong homology to the SERA gene has been
identified in P. falciparum (23). This gene, termed
SERPH, encodes a protein that is also localized to the
parasitophorous vacuole and that has very similar characteristics to
SERA, including the presence of a centrally located papain-like
protease domain. The likely presence of at least one other
SERA gene homologue has also been reported (10). Recently,
nucleotide sequencing of P. falciparum chromosome 2 identified the presence of eight SERA-like genes located in
a cluster in a central region of the chromosome (24). These
SERA genes are arranged in a head-to-tail array with
SERA and SERPH the fifth and sixth genes in the
cluster, respectively. A similar cluster of five SERA-like
genes has been identified in Plasmodium vivax (25),
and further homologues have been discovered in the rodent malaria
parasite Plasmodium vinckei (26). The presence of relatively
large SERA multigene families in divergent
Plasmodium species suggests an important biological role for
the proteins encoded by these genes.
Whereas all the SERA proteins are predicted to possess a central domain
with strong homology with the papain family of cysteine proteases,
some, including SERA itself, were found to contain a highly unusual
cysteine to serine substitution in the active site position (6, 7, 24).
Furthermore, in certain P. vivax and P. vinckei
SERA homologues, substitutions were observed in other important
catalytic site residues, raising the possibility that at least some of
these molecules may no longer function as proteases (25). Importantly,
however, the protease domain of some SERA homologues, including SERPH,
have no such substitutions.
Very little is known about the function of the SERA proteins, and the
fundamental reason for the requirement of so many homologues is
unknown. In this paper, we analyze the expression of the eight chromosome 2 SERA genes using a combination of RT-PCR,
microarray, antigenicity studies and gene "knockout" approaches. We
also identify and similarly characterize a ninth SERA
homologue present on P. falciparum chromosome 9. These
studies reveal that genes in the central region of the chromosome 2 cluster, but not those toward the periphery, are expressed in mature
blood stage forms and appear to play an important role in maintenance
of the erythrocytic cycle.
 |
EXPERIMENTAL PROCEDURES |
Parasite Culture and Transfection--
P. falciparum
parasites were cultured and synchronized as per standard procedures
(27, 28). Enriched trophozoite and schizont preparations used in
Western blot analysis were obtained by Percoll purification (29). Ring
stage parasites (~5% parasitemia) were transfected with 80 µg of
purified plasmid DNA (Plasmid Maxi Kit; Qiagen) as previously described
(30) except using modified electroporation conditions (31). Parasites
were cultured in a 10-cm culture dish for 48 h prior to selection
with 2.5 nM WR99210. Transfected parasites were visible
after 3 weeks of continuous culture. Parasites containing integrated
forms of the plasmid were obtained by drug cycling, where drug was
removed for 2-3 weeks before being reapplied.
SERA Gene Prediction and Amino Acid Sequence Alignment--
The
presumptive sequence of SERA proteins encoded in genomic fragments of
Plasmodium chabaudi, Plasmodium knowlesi, and
Plasmodium yoelii was determined with the help of a program
that was trained for ab initio gene prediction in P. falciparum and additionally uses an informant protein
sequence3 and by manually
checking the quality of the resulting multiple alignment. The sequence
of SERA6 was used as the informant sequence. The protease domain always
resides entirely in the longest and terminal exon of the predicted
genes, and its well conserved sequence could therefore be determined
with high confidence. All the predicted genes also possess the strongly
conserved terminal cysteine-rich block, which is characteristic for the
SERA class of proteases, within the same exon. Multiple alignments were
performed with the ClustalW program (32) using default parameters. The
sequence was subdivided into regions representing the blocks of strong conservation and the poorly aligned spacers between these blocks. Pairwise identity in a region was computed by realigning the two subsequences using the Smith-Waterman algorithm and averaging over all pairs.
Microarray Analysis--
Oligonucleotide microarrays were
printed on polylysine-coated microscope slides comprising 6912 P. falciparum 70-mer oligonucleotides, in duplicate (Operon
Technologies). Highly synchronous parasite cultures were obtained by
triple sorbitol treatment and used to measure SERA gene
expression levels between mature (trophozoite/schizont) and young
(ring) stage 3D7 parasites. Parasitized erythrocytes were lysed by
saponin lysis, and the RNA was extracted using RNeasy minicolumns
(Qiagen) according to the manufacturer's instructions. Total RNA (20 µg) was reverse transcribed overnight using SuperScript II
(Invitrogen) according to the manufacturer's instructions with a modification of the dNTP stock that resulted in final concentrations of 500 µM dATP, dCTP, and dGTP and 250 µM
dTTP and 5-(3-aminoallyl)-dUTP (Sigma; catalog no. A0410). The reactive
amino group of 5-(3-aminoallyl)-dUTP was used to conjugate 2 µg of
the purified cDNA preparations with 100 µg of the fluorescent dye
esters, NHS-Cy3 (Amersham Biosciences; catalog no. PA23001) and NHS-Cy5
(Amersham Biosciences; catalog no. PA25001). Microarrays were
hybridized overnight at 42 °C with 500 ng of each fluorescently
labeled probe in 25% formamide, 5× SSC, 0.1% SDS. Arrays were washed
twice at room temperature with 1× SSC, 0.2% SDS, followed by two
stringent washes (0.1× SSC) prior to scanning on a ScanArray 4000 (GSI
Lumonics). Data was extracted from the raw images using
Spots4 and mined in
GeneSpring (Silicon Genetics).
Nucleic Acid Analysis--
Genomic DNA was isolated from mixed
trophozoite/schizont stage parasites as described (34). Manipulation of
recombinant DNA and analysis of nucleic acids by Southern blot
hybridization were carried out using standard procedures (35). DNA was
labeled with [
-32P]dATP using the Bresatec DNA
labeling kit as per the manufacturer's instructions. Unincorporated
nucleotides were removed using ProbeQuantTM G-50 Micro
Columns (Amersham Biosciences). For RT-PCR, P. falciparum D10 total RNA was isolated from saponin-lysed (0.15% saponin) infected
erythrocytes using the RNeasy minikit as per the manufacturer's instructions (Qiagen). RT-PCR was performed on the extracted RNA using
the Superscript First Strand Synthesis System (Invitrogen). SERA genes were amplified from the cDNA with
Taq polymerase (Invitrogen) using the following
oligonucleotides (restriction sites are underlined): SERA1/for
(5'-AAACTCGAGTTGGATGAATTTAGTGATTC) and SERA1/rev
(5'-CTAACTCGAGATCTACTAATGTTCCATTCG), SERA2/for
(5'-AATCTCGAGCAATTGGAACCTCGATTTATG) and SERA2/rev
(5'-CACTCGAGATCTGTCAGTATACCACTTAC), SERA3/for
(5'-ATCTCGAGTATACGAAGAGAAATCTGC) and SERA3/rev
(5'-TTCTCGAGCTACTTCATTTTTTAGATCTTACTC), SERA4/for
(5'-ACTCGAGTTATCATCA GAATTAGCACCAC) and SERA4/rev
(5'-TCTCGAGTGATCTTTCAGATCTCCATTC), SERA5/for
(5'-GCTCGAGTACGGAGAAACAAAAGATACTAC) and SERA5/rev
(5'-CTCTCGAGTTTAAGATCTAATCATCAAC), SERA6/for
(5'-CCTCGAGCCTCACATCTTAATTTATGCC) and SERA6/rev
(5'-TTCTCGAGTATCCATAGATCTACATTC), SERA7/for
(5'-TCTCGAGTACAAGATAAGGATTCTAAAC) and SERA7/rev
(5'-TCTCGAGAAGATCTAACATTCCACTTC), SERA8/for
(5'-GGGACCTCGAGTTTACAAAAATGTATTTCATGTG) and SERA8/rev (5'-GGTTTCTAAATAGTACGAAAGATCTCCACCCTC), SERA9/for
(5'-CTCATAGGATCCTTTTCCTTTTTTTCTTAATTTTATTCC) and SERA9/rev
(5'-CTTTATTTTCTCGAGAAATAAAATTATAGCATAC), KAHRP/for (5'-ATGAAAAGTTTTAAGAACAAAAATACT) and KAHRP/rev
(5'-CTGTTCCCTGGGGTTGTTGAGGTTG).
Protein Expression and Purification--
The DNA sequences
corresponding to the N-terminal regions of SERA1-9 genes
were amplified from P. falciparum (D10) genomic DNA using
the following oligonucleotides (restriction sites are underlined):
SERA1N/for (5'-GTAATTCGTACAAGGGGGGGATCCGATG) and SERA1N/rev (5'-TTTAGACTCGAGATTATTGGGTGACCTTG), SERA2N/for
(5'-ATAA AGAGTGGATCCACTACAGATGAATCTGC), and SERA 2N/rev
(5'-GGTGATATCTTTGTTCCTCGAGATCCTCC), SERA3N/for
(5'-GTCTTGTTTTGTAA AAATGACATAGAATTCACAAC) and SERA3N/rev (5'-CCACCATTGGTGAATTCTTTATTGG), SERA4N/for
(5'-GGAGGTGATACAGAATTCCATCCAGGTACTCCTCC) and SERA 4N/rev
(5'-GTAGATGAAGAATCGAATTCTCCTTGGGAACC), SERA5N/for (5'-GTTATATTTAACAAGGATCCTATAAAATCTACAGG) and SERA5N/rev
(5'-GATTTTACTTGAATTCATCCTGTTTTTTC), SERA6N/for
(5'-GTGACTGTGATATCACAGAATTCTGGACATAAC) and SERA6N/rev (5'-CAAATCATCGGAACGAATTCTTTTATTTGAAGG), SERA7N/for
(5'-GGTGAGCAAGGAATTCCAAATTCACC) and SERA7N/rev
(5'-GGAAGTGGAATTCGAGTTACAAGAGC), SERA8N/for
(5'-GGGTTTACACGATTTTAGTAGGAATTCCGATG) and SERA8N/rev
(5'-CCATTGATTAGAATTCTTTAAACATAAAGC), SERA9N/for (5'-CATCTGTTTCTGGATCCGTTGATTCTG) and SERA9N/rev
(5'-ACCAACATTTTCTTTTAAAACTCGAGATTTAATTTAATCG). The
resulting PCR products were ligated into the appropriate pGEX vectors
and expressed in Escherichia coli BL21 cells (Stratagene) as
glutathione S-transferase (GST) fusion proteins (36). GST fusion proteins were harvested by suspending bacteria expressing SERA
proteins in 30 ml of Bug BusterTM (Novagen) in the presence of
CompleteTM protease inhibitor mixture tablets (Roche Molecular Biochemicals) for 30 min followed by sonication. The SERA proteins were
purified from the supernatant using glutathione-Sepharose as described
by the manufacturer (Amersham Biosciences). GST alone was produced
using the pGEX-4T-1 plasmid. The GST fusion proteins and GST alone were
dialyzed overnight in PBS before further use.
Generation of SERA Antibodies--
To generate SERA
antisera, 6-week-old female BALB/c mice and 3-month-old
New Zealand White rabbits were immunized with 40 and 150 µg of SERA
GST fusion proteins, respectively, in Freund's complete adjuvant.
Animals were boosted three times with 35 and 120 µg of protein in
Freund's incomplete adjuvant 5 weeks post injection, after which the
animals were bled for serum collection. Anti-GST antibodies were
removed from rabbit serum using a GST-bound CNBr-activated Sepharose 4B
column (Amersham Biosciences) according to the manufacturer's
instructions. Anti-SERA IgG fractions were further isolated by applying
the rabbit serum to a Protein G-Sepharose column (Amersham
Biosciences). Total IgG was eluted from the column with 0.1 M glycine, 0.15 M NaCl (pH 2.6). Eluted
fractions (2 ml) were neutralized using 200 µl of 2 M
Tris, pH 8.0.
SDS-PAGE and Western Blotting--
Parasite proteins obtained
from enriched trophozoite and schizont preparations were separated on
6, 12, and 15% SDS-PAGE reducing gels and transferred to
nitrocellulose membranes. Membranes were probed with either rabbit
anti-SERA1-9 polyclonal antibodies or pooled human sera derived
from adults living in Papua New Guinea (denoted PNG-P, PNG-M, or PNG-B)
(37). Melbourne serum was collected from nonmalaria exposed individuals
currently living in Melbourne, Australia. Horseradish
peroxidase-conjugated sheep anti-rabbit or sheep anti-human IgG
(Silenus Laboratories) were used for detection, and bands were
visualized by enhanced chemiluminescence (PerkinElmer Life Sciences).
Indirect Immunofluorescence--
Smears of RBC infected with
P. falciparum D10 late stage shizonts were fixed with
ice-cold 100% methanol for 2 min and incubated with IgG-purified
anti-rabbit SERA1 to -9 polyclonal antibodies and co-incubated with
mouse anti-SERA5 antibody. Secondary antibodies were a mixture of
fluorescein isothiocyanate-conjugated sheep anti-rabbit IgG (Silenus
Laboratories) and rhodamine-conjugated goat anti-mouse IgG (Dako). Dual
color fluorescence images were captured using a Zeiss fluorescent microscope.
 |
RESULTS |
Centrally Located SERA Genes Are Transcribed More Strongly than
Peripheral SERA Genes in Mature Blood Stages--
A search of the
P. falciparum data base (available on the World Wide Web at
www.PlasmodDB.org) revealed the presence of nine SERA gene
homologues, eight in a cluster on chromosome 2 (24) and one on
chromosome 9 (Fig. 1). In this paper,
these genes are referred to as SERA1-SERA9, with
SERA5 and SERA6 being the previously described
SERA/SERP and SERPH genes, respectively (3, 38). Ironically, only SERA5 encodes an N-terminal serine stretch
from which the family derives its name. All genes are predicted to possess the four-exon structure characteristic of SERA genes
in this and other Plasmodium species with the exception of
SERA8, which is predicted to possess an additional exon and
a premature stop codon. All SERA homologues encode a
centrally located "papain-like" protease domain, although in
SERA1-SERA5 and in SERA9 the active site cysteine residue is present
as a serine. Phylogenetic analysis performed on all known
Plasmodium SERA genes reveals that SERA9 is most
closely related to the other P. falciparum SERA genes with
an "active site" serine.5
The origins and function of this "rouge" SERA gene remain to be determined; however, at present, there are no obvious features that
distinguish this gene from SERA1-SERA5.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Genetic organization of the SERA
locus and transcription of SERA genes in blood
stage parasites. A, chromosomal location and
orientation of the chromosome 2 SERA locus relative to the
location of a locus encoding merozoite surface proteins 2, 4, and 5 (MSP locus) and KAHRP (24, 39). The SERA locus on chromosome
9 appears to consist of a single gene. Predicted encoded catalytic
residues are indicated below each gene. B,
SERA gene structure. Exons are denoted by boxes,
and lines linking boxes represent
introns. SERA genes 1-9 were amplified from cDNA and
gDNA across the region indicated by the dotted
line. C, PCR analysis of SERA genes
from late stage parasites (trophozoites/schizonts). SERA1-9
were amplified from gDNA and cDNA. Expected fragment sizes are
displayed below each panel. Molecular weight
markers are denoted (M). Amplification of the
SERA genes from gDNA is displayed in the left
lane of each panel, whereas gene amplification
from cDNA is seen in the right lane.
|
|
RT-PCR analysis was used to determine which members of the
SERA multigene family are expressed in parasitized
erythrocytes. Initially, cDNA was synthesized by reverse
transcription of parasite RNA isolated from an asynchronous culture of
P. falciparum parasites (D10 line) using a poly(dT) primer.
This material was subjected to PCR using primers specific for each
SERA gene amplifying across two introns as shown in Fig.
1B. The same primers were also used to amplify the genes
from parasite gDNA. Appropriately sized gDNA and cDNA fragments
were detected on an ethidium bromide-stained agarose gel (Fig.
1C). Sequencing of these PCR products confirmed the
identification of the amplicons and of the intron/exon boundaries. It
should be noted that although these fragments were sequenced for
correct identification of each gene, rather than to identify polymorphisms, the sequence obtained from the D10 parasite line was
almost identical to that published for 3D7 for each gene (24). These
results indicate that each of the nine SERA genes is
transcribed in blood stage parasites.
In order to investigate the transcriptional regulation of the
chromosome 2 SERA genes, parasite RNA isolated from the same number of synchronized ring, trophozoite, and schizont stage parasites (D10 line) was subjected to RT-PCR as described above. Appropriately sized cDNA fragments representing these eight SERA genes
were detected in mature parasites but not in early stage parasites (Fig. 2). The presence of
SERA5 and SERA6 mRNA in mature blood stage
forms of the parasite has previously been described (3, 23, 10),
consistent with the above results. Although not strictly quantitative,
it appears from this experiment that maximal expression for each of the
eight chromosome 2 SERA genes occurs in mature parasites.
This is in contrast to the expression pattern for the KAHRP
control that is transcribed earlier in the parasite life cycle as
expected. Note that since the SERA9 gene was not available until relatively recently, it was not included in this experiment. However, in a separate time course experiment, mRNA from
SERA9 appeared to be regulated similarly to the other SERAs
(data not shown).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 2.
Reverse PCR analysis of
SERA- and KHARP-specific transcripts
in tightly synchronized D10 parasites. The panels
represent amplification of each SERA gene across the region
indicated in Fig. 1B. M, molecular weight
markers. Lane 1, early ring stage;
lane 2, late ring stage; lane
3, early trophozoite stage; lane 4,
late trophozoite stage; lane 5, early schizont
stage; lane 6, late schizont stage.
|
|
To further examine SERA transcription, we used microarray
analysis to measure the extent of increase in transcription of
SERA mRNA from young blood stage forms (rings) to mature
forms (trophozoites/schizonts). By this analysis, only the centrally
located SERA genes in the chromosome 2 cluster, as well as
SERA9, showed a significant increase in expression in mature
forms (Fig. 3A). In addition,
SERA5 appeared to be substantially more strongly transcribed
than other SERA genes. A repeat set of microarray
experiments in which the two mRNA samples were labeled with the
alternate fluorescent dye revealed almost identical results (Fig.
3B). It should be noted that the microarray datum included
here was part of a genome-wide expression analysis that revealed
several "hot spots" of mRNA expression increase from young to
mature forms.6 On chromosome
2, the SERA and MSP2/4/5
(39) loci were the most obvious in this regard.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Microarray analysis of SERA
gene expression. Bar graphs represent
the relative gene expression of individual SERA genes.
A, white bars indicate the normalized
gene expression ratio of Cy3/Cy5 between trophozoite/schizont
(T/S) stage parasites (n = 8)
(46). The normalized gene expression ratio (relative increase = 1)
is represented as a dashed line. Black
bars indicate the relative gene expression ratio of a
comparison between trophozoite/schizont (Cy5) and ring stage
(R) (Cy3) 3D7 parasites (n = 4).
Error bars represent S.E. B,
white bars indicate the normalized gene
expression ratio of Cy3/Cy5 between trophozoite/schizont stage
parasites (n = 8). Black bars
indicate the relative gene expression ratio of a dye-swap comparison
between trophozoite/schizont (Cy3) and ring stage (Cy5) 3D7 parasites
(n = 4). Error bars represent
S.E.
|
|
Only Proteins Encoded by Centrally Located SERA Genes Are Detected
in Blood Stage Parasites--
We aimed to generate antibodies specific
for each of the SERA proteins. To identify variable regions suitable
for recombinant protein expression, we aligned the amino acid sequences
of the nine P. falciparum SERAs together with full-length
SERA homologues identified in P. vivax (25), P. knowlesi, and several rodent malaria species that we identified by
interrogation of Plasmodium sequence data bases (available
on the World Wide Web at www.PlasmoDB.org). Six highly conserved
blocks were identified, five of which shared ~45% amino acid
identity across the family (Fig. 4). The
remaining region (block 5) encompasses the protease-like domain and is
even more conserved showing ~60% identity. In contrast, a number of highly variable regions were identified, the most divergent of which is
at the N terminus (Fig. 4, solid line). This
region shares less than 10% identity between any two SERA proteins.
Moreover, it is universally hydrophilic and, in the case of SERA5, has
been shown to be immunogenic (14, 17, 40). Hence, the N-terminal 50-100 residues of each P. falciparum SERA were expressed
in E. coli as a GST fusion protein, and antiserum to each
was raised in both rabbits and mice.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Summary of a pairwise comparison of predicted
SERA proteins. Data were derived from an alignment of all the
full-length SERA protein sequences found in the malaria PlasmoDB data
base at the time of writing and included members from P. falciparum (eight sequences, with SERA8, a likely
pseudogene, being excluded from the analysis), P. vivax
(five sequences), P. chabaudi (one sequence), P. knowlesi (five sequences), and P. yoelii (four
sequences)). The position of the active site cysteine/serine is
indicated (asterisk), as are the known processing sites in
the SERA5 protein (arrows).
|
|
To investigate the specificity of the rabbit antisera, each was
tested for reactivity with a panel of SERA1-SERA9 GST fusion proteins
by Western blotting following depletion of GST-reactive antibodies.
Antiserum to each immunogen recognized only the respective fusion
protein (Fig. 5). Since the expressed
regions are mostly overlapping, this result suggests that specific
antibodies had been raised to the SERA region of each fusion
protein.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 5.
Western blot analysis of SERA recombinant
proteins using SERA polyclonal antisera.
Recombinant SERA proteins 1-9 (20 ng) were separated on a 12%
polyacrylamide gel under reducing conditions and stained with Coomassie
Brilliant Blue (top panel). Nine identical gels
were transferred to nitrocellulose membranes and probed individually
with rabbit anti-SERA1 to -9 polyclonal antibodies. The antiserum used
to probe each membrane is indicated at the left.
|
|
These same rabbit antisera were tested for reactivity with D10 parasite
proteins extracted from purified schizonts by Western blotting (Fig.
6A). Only anti-SERA4,
anti-SERA5, and anti-SERA6 antibodies reacted strongly with proteins in
the size range expected for full-length SERA proteins (100-130 kDa).
This was also the case when parasite proteins from two other parasite
lines, 3D7 and W2mef, were analyzed (data not shown). A similar panel
of mouse antisera also reacted strongly to identically migrating parasite proteins in the appropriate lanes (data not shown). In contrast, the strongly reactive species observed in the rabbit anti-SERA7 lane (Fig. 6A) appeared to migrate too slowly for
it to represent a SERA protein. Moreover, this protein was not detected by mouse anti-SERA7 antibodies, nor did it appear to localize to the
parasitophorous vacuole by indirect immunofluorescence analysis (data
not shown). Most importantly, this large molecular weight species was
still detected in a parasite line in which the SERA7 gene
was disrupted by gene targeting (see below; data not shown). A
relatively weakly reactive species at ~85-90 kDa was consistently
observed with SERA9 antibodies (Fig. 6A).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
Western blot analysis of P. falciparum (D10 line) schizont parasite proteins using
rabbit polyclonal antisera SERA1-SERA9.
A, parasite proteins corresponding to a mixed population of
trophozoites and schizonts (~2 × 106 parasites)
were separated on a 10% polyacrylamide gel under reducing conditions
and probed with rabbit anti-SERA1 to -9 polyclonal antibodies. The
antiserum used to probe each membrane is indicated at the
top of the lane. Molecular weight markers are
shown to the left of the membrane. B, in order to
further examine the specificity of rabbit polyclonal anti-SERA4-6,
parasite proteins corresponding to a mixed population of trophozoites
and schizonts (2 × 106 parasites) were separated on a
10% polyacrylamide gel under both reducing and nonreducing
conditions.
|
|
It has previously been shown that full-length SERA5 migrates slightly
more rapidly that SERA6 in SDS-PAGE gels under reducing conditions (14,
17, 40). This is consistent with the differences in the sizes observed
here, although the actual molecular weights of these species appear a
little smaller by our analysis. SERA4 protein has not been identified
previously, and this protein appeared to migrate similarly to SERA5 at
an apparent molecular mass of ~100 kDa under reducing
conditions (Fig. 6, A and B). Western blotting
was also performed under nonreducing conditions in order to confirm
that these species were indeed derived from different gene products. By
this analysis, SERA4, SERA5, and SERA6 species are clearly separated
(Fig. 6B). Also apparent under these conditions was the
disappearance of more rapidly migrating species observed in the SERA5
and SERA6 lanes under reducing conditions. It is likely that these
fragments represent disulfide-bonded processing products of these
proteins that are known to accumulate in mature blood stage forms. To
determine the subcellular localization of SERA4, indirect
immunofluorescence was performed on schizont-stage parasites (D10
line). Both SERA5 and SERA6 are known to localize to the
parasitophorous vacuole (1, 2, 23). Double labeling experiments
revealed that SERA4 co-localizes with SERA5 (Fig. 7A). Consistent with
parasitophorous vacuole staining, fluorescence was limited to the
parasite but excluded from the merozoite, giving a "channeled"
appearance in segmented schizonts. Furthermore, SERA4 also appeared to
co-localize with the membrane-anchored merozoite surface protein 1 (MSP-1) in mature (segmented) schizonts, also consistent with a
parasitophorous vacuole location for SERA4 (Fig. 7B). Double
labeling performed in parallel except using a prebleed serum in place
of the SERA4 antibodies confirmed the specificity of the SERA4 reagent
(Fig. 7C). We caution that given that this is the first time
the localization of this molecule has been examined, further studies
using different reagents and approaches (e.g. confocal
microscopy and/or electron microscopy) are required to confirm the
localization of SERA4.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 7.
Co-localization of SERA4 with SERA5 and MSP-1
in late stage parasites. A, smears of parasite
(D10)-infected RBC were reacted with rabbit anti-SERA4
( SERA4) and mouse anti-SERA5 ( SERA5) polyclonal
antisera. The images (left to right)
are light, 4',6-diamidino-2-phenylindole (DAPI), fluorescein
isothiocyanate (FITC; anti-SERA4 rabbit polyclonal
antibody), rhodamine (anti-SERA5 mouse polyclonal antibody), and merged
(overlay of fluorescein isothiocyanate and rhoadamine image).
B, co-localization using the SERA4 antibody with the
monoclonal antibody 4H9/19 ( MSP-1) to detect MSP-1 (33, 47).
C, as for B except using normal rabbit
sera (NRS) derived from the same rabbit used to
derive SERA4 antibodies prior to the first immunization.
|
|
Antibodies to SERA2-5 Are Elicited in Response to Natural
Infection--
In order to examine the possibility that other SERA
proteins might be expressed in parasite populations in the field, the panel of recombinant SERA proteins were examined for reactivity to
three different sets of pooled human antisera by Western
blotting (Fig. 8). These sera were
derived from adult Papua New Guineans resident in areas of intense
P. falciparum transmission (37). These individuals are
likely to have been infected on numerous occasions with P. falciparum and are considered clinically immune to malaria.
Recombinant SERA4 was recognized by all three pools of human
sera, whereas SERA2, SERA3, and SERA5 fusion proteins were
recognized by one or two of the PNG pooled sera. The finding that not
all PNG sera recognize the SERA5 recombinant antigen is consistent with
a previous study using sera from Ugandan adults living in a holoendemic
area (41). In contrast, other recombinant SERA proteins were not
recognized by any of the PNG antibodies. As expected, the pooled
sera from non-malaria-exposed individuals (Fig.
8, Melb) did not react with
any of the recombinant SERA proteins when tested in parallel Western
blots (note that PNG-B and non-malaria-exposed pools were tested at the
same time under identical conditions). This result provides evidence
that SERA2 and SERA3, in addition to SERA4-SERA6, may also be
expressed in some P. falciparum parasites.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 8.
Western blot analysis of SERA recombinant
proteins using human sera. Recombinant SERA
proteins (20 ng) 1-9 were separated on a 12% polyacrylamide gel under
reducing conditions and stained with Coomassie Brilliant Blue
(top panel). Four identical gels were transferred
to nitrocellulose membranes and probed individually with PNG-P, PNG-M,
PNG-B, and Melbourne sera (Melb). The antiserum used
to probe each membrane is indicated at the left.
|
|
Most Genes Located at the Periphery of the SERA Cluster Are Not
Essential to Blood Stage Growth--
The expression data described
provided evidence for the expression in blood stages of detectable
levels of SERA4, SERA5, and SERA6 proteins, but not of other SERAs, in
D10 and 3D7 parasite lines. In order to test whether this expression
pattern corresponded to an essential role in blood stage growth, each
gene in the chromosome 2 SERA locus
(SERA1-SERA8) was targeted for genetic disruption by single
crossover recombination (30, 42, 43). Note that since the
SERA9 gene was identified only relatively recently, it has
not yet been targeted for disruption. An internal region of each of the
SERA genes 1-8 (~1 kb) was cloned into the transfection vector pHH1 to facilitate gene targeting (Fig.
9) (44). Each plasmid was transfected
into D10 parasites, and drug-resistant populations were derived
following transfection. These eight transfected lines containing each
of the different plasmids were selected to obtain parasites with
integrated forms of the plasmid.

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 9.
Strategy for targeted disruption of
SERA genes by single crossover homologous
integration. Schematic representation of the pHH1- SERA1 to -8 transfection plasmids (all of which were ~7 kb in size) and
SERA endogenous locus (wild type) are shown. The targeting
region is indicated by the gray shaded
region. The presence of the selectable marker cassette
(hDHFR) in the plasmid is indicated. To demonstrate how Southern blot
analysis was performed, the presence of a theoretical restriction
endonuclease site termed A is shown. Endogenous
(E), plasmid (P), and the integration
(In) specific fragments that result from digestion with
enzyme A and the probing of blots with the specific targeting region
(gray) are indicated.
|
|
To test whether transfected plasmids had integrated into the
corresponding SERA genes on chromosome 2, Southern blot
analysis was used to probe restriction endonuclease-digested gDNA from both parental D10 and transfected parasite populations. Filters were
probed with DNA fragments encompassing the unique targeting sequence in
each plasmid (Figs. 9 and 10). The
enzymes used were chosen to reveal a distinct size difference in
fragments representing wild-type locus, integrated locus, and episomal
plasmid when the blots are hybridized to a targeting sequence
probe.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 10.
Southern blot analysis of genomic DNA from
transfected parasites. Schematic representation of the wild type
endogenous chromosome 2 SERA locus is shown at the
top. Solid lines under the
exons represent the location of the gene targeting sequences cloned
into BglII/XhoI-digested pHH1 transfection
plasmid (44). Southern blots summarizing the result of the attempted
targeted disruption of each SERA are shown below
each respective gene. Genomic DNA from each transfected line following
drug cycling (no cycling (C0), 1 cycle (C1),
etc.) and parental D10 parasites were restriction-digested, separated
on a 0.6% agarose gel, and transferred to nitrocellulose. The
membranes were probed with each respective targeting sequence. The
positions of endogenous (E), plasmid (P), and
integration-specific fragment events (In) are indicated, and
their molecular weights are given below each relevant
Southern blot. The disappearance of the endogenous band, which
indicates that integration has occurred into the target gene, is shown
by asterisks in the SERA2, SERA3,
SERA7, and SERA8 panels.
|
|
By this analysis, it was evident that all plasmids were transfected
correctly and were initially maintained in an episomal form as expected
(Fig. 10). Following selection for integration, it was evident that
plasmids designed to disrupt SERA2, SERA3, SERA7, and SERA8 had integrated by single
crossover homologous recombination into their respective genetic loci
(Fig. 10). In these parasite populations, the complete disappearance of
the fragment representing the endogenous locus, together with the appearance of fragments representing the targeted locus, confirmed that
the vast majority of parasites in these populations possessed correctly
integrated forms of the plasmid. It should be noted that plasmids that
integrate by single crossover recombination often insert more than one
plasmid copy into the locus. If this has occurred, a band corresponding
to that expected for the episomal plasmid will be observed in
populations that possess completely integrated forms of the plasmid.
This appears to be the case in the SERA3, SERA7, and SERA8 disruption
lines (Fig. 10). Southern blot analysis of pulsed field gels confirmed
the complete integration of the SERA2, SERA3, SERA7, and SERA8 plasmids
into chromosome 2 and the absence of any detectable episomally
replicating plasmids (data not shown).
Plasmids designed to disrupt SERA4, SERA5, and
SERA6 did not integrate by homologous recombination but
remained episomal throughout the selection procedure (Fig. 10).
Repeated attempts to disrupt these genes using single crossover
technology, including in the 3D7 parasite line, were similarly
unsuccessful (data not shown). SERA1 was only targeted for
integration on the one occasion, and this was unsuccessful with the
plasmid targeting elsewhere in the genome seemingly by nonhomologous
recombination, a rare although previously described event in this
parasite (Fig. 10) (30).
These data indicate that individually SERA2,
SERA3, SERA7, and SERA8 are not
absolutely necessary for blood stage growth of D10 parasites. It
remains possible, however, that these genes are important for another
stage of the life cycle or are differentially expressed and encode
proteins that have an important function that can be complemented by
expression of another SERA. In contrast, the inability to disrupt
SERA4, SERA5, and SERA6 in the D10
line (and in some cases also in 3D7), together with their apparent strong expression in the blood stages of these lines (summarized in
Table I), is consistent with an important
role for some or all of these genes during the erythrocytic cycle.
 |
DISCUSSION |
Sequencing of the P. falciparum genome has unveiled the
presence of numerous genes that show strong homology to well
characterized parasite proteins. The related blood stage proteins SERA
and SERPH (termed SERA5 and SERA6 throughout this study) were described more than 10 years ago, and numerous publications further
characterizing these molecules have emerged in the ensuing period.
Somewhat surprisingly, it is now apparent that the genome contains at
least nine SERA-like genes, eight in a cluster on chromosome
2 and one on chromosome 9 (24) (PlasmoDB data base). Other
Plasmodium species also appear to contain relatively large
SERA gene families (25, 26). Our interest in the work
described here was to begin to explore the biological purpose of the
P. falciparum SERA genes by analyzing expression profiles
and potential functional redundancy across this family.
Our first observation was that all SERA genes appear to be
expressed and co-regulated at the mRNA level. Both RT-PCR and
microarray experiments highlighted the accumulation of mRNA of
SERA family members in mature blood stage forms of the
parasite. It did not appear, however, that all members were expressed
to equal levels. Microarray analysis performed using the 3D7 parasite
line revealed very little increase in transcription in mature stages of
SERA genes located at the periphery of the chromosome 2 cluster (particularly SERA1, -2, and
-8) when comparing mRNA prepared from immature parasites
(ring stage) with that from mature forms (trophozoite-schizont stages).
In contrast, all other SERA genes showed a significant increase in transcription by this analysis, with SERA5
showing the greatest increase in expression. We note that the absolute values obtained here should be treated with some caution, however, since the technical limitations of microarray (e.g.
different target sequences may favor adherence to the glass slide
and/or hybridization to the probe) do not always allow for accurate
quantitation of transcription increase.
Consistent with the microarray data, we detected some evidence of
protein expression in blood stages of the molecules encoded by genes
centrally located in the chromosome 2 SERA locus as well as
by the SERA9 gene. Species that corresponded to
SERA4-SERA6 were easily detected in three laboratory lines
tested (D10, 3D7, and W2mef). SERA5 and SERA6 have of course already
been described in the literature, but SERA4 has not been detected
previously. This protein is synthesized as a 100-kDa protein that
co-localizes with SERA5 in the parasitophorous vacuole. Whether it is
subjected to complex proteolytic processing events like SERA5 remains
to be investigated (13). An ~85-kDa species was detected with rabbit anti-SERA9 antibodies; however, we have not yet confirmed the identity
of this polypeptide with independently derived mouse antibodies.
Although we did not detect other SERA proteins in parasite extracts
with the specific antisera raised for this study, antibodies
specific for SERA2 and -3 recombinant proteins were detected in pooled
groups of serum from P. falciparum immune
individuals. This suggests that these family members may also be
expressed in at least some parasite lines. It remains possible that
SERA2 and -3 are also expressed in the laboratory lines tested here, but the antibodies raised to the N-terminal fusion proteins do not
recognize the corresponding native parasite proteins. Notably, however,
the ability to disrupt these genes is consistent with an absence of
expression in the D10 laboratory line.
With respect to the targeted gene disruption experiments, a strong
correlation was evident between those genes that could be disrupted and
those that showed little or no evidence of protein expression in the
laboratory line tested (summarized in Table I). SERA2,
-3, -7, and -8 were all disrupted by
single crossover recombination technology. This process relies on the
gene targeting event having little or no effect on blood stage growth,
since the methodology depends on parasites possessing integrated forms of the plasmid outgrowing those containing episomally replicating forms
(30, 42, 43, 45). Hence, SERA2, -3,
-7, and -8 are all either not involved, or play a
redundant role, in the erythrocytic cycle.
In contrast, it did not appear possible to disrupt SERA4,
-5, and -6 despite repeat attempts in both the
D10 and 3D7 parasite lines. Together with the strong expression of the
proteins encoded by these genes, this result implicates an important
role for some or all of these genes in blood stage growth in these
laboratory parasite lines. We were unable to disrupt the
SERA1 gene in the one attempt shown in this paper.
Although the possibility remains that SERA1 is playing a role in the
erythrocytic cycle, given that SERA1 mRNA showed little
increase in expression in mature stages and that SERA1 protein
expression was not evident in laboratory or field isolates, we consider
this unlikely and suspect that repeat attempts at targeting this
gene may be successful.
Taken together, the data presented here suggest that whereas all genes
in the chromosome 2 SERA cluster have the capacity to be
expressed late in the blood stage cycle, those toward the center
(SERA4-SERA6) appear to be important to the replication of
the laboratory lines tested. Low or absent expression and/or the
ability to disrupt the peripherally located genes in the cluster (SERA1-SERA3 and SERA7 and -8) raises
the possibility that some of these may be pseudogenes. This is even
more likely in the case of SERA8 that appears to possess a
frameshift mutation that induces a premature stop codon (24). As
alluded to above, however, it appears that at least some of these
"dispensable" genes (most notably SERA2 and
-3) may be expressed at a protein level in at least some
parasite lines. Another possibility, not addressed here, is that some
SERAs are expressed at different stages of the parasite life cycle.
Whereas the biological role of the SERA family remains unknown, it is
clear from this study that only a subset of the family are necessary to
normal blood stage growth of the parasite. It is interesting that this
subset includes members that possess catalytic serine (SERA4 and SERA5)
and cysteine (SERA6) residues consistent with a (presumably
different) role in the erythrocytic cycle for both types of protease.
The intriguing possibility remains, however, that there is functional
redundancy among the SERAs and that expression profiles may alter in
relation to certain stimuli such as immune pressure and/or red blood
cell diversity.
 |
ACKNOWLEDGEMENTS |
We thank Toshihiro Horii and colleagues for
sharing unpublished data prior to publication. We are grateful to
Rebecca O'Donnell for input into this work and to John Reeder, Moses
Bockarie, and other colleagues from the Papua New Guinea Institute of
Medical Research for the provision of PNG sera used in this
study (MRAC project no. 01.05) and the Australian Red Cross Blood Bank
for the provision of other human blood and serum. We thank the
scientists and funding agencies comprising the international Malaria
Genome Project for making sequence data from the genome of P. falciparum (3D7) public prior to publication of the completed
sequence. The Sanger Centre (UK) provided sequence for chromosomes 1, 3-9, and 13, with financial support from the Wellcome Trust. A
consortium composed of the Institute for Genome Research, along with
the Naval Medical Research Center, sequenced chromosomes 2, 10, 11, and
14, with support from NIAID (National Institutes of Health), the
Burroughs Wellcome Fund, and the Department of Defense. The Stanford
Genome Technology Center sequenced chromosome 12, with support from the
Burroughs Wellcome Fund. The Plasmodium Genome Database is a
collaborative effort of investigators at the University of Pennsylvania
and Monash University (Melbourne, Australia), supported by the
Burroughs Wellcome Fund.
 |
FOOTNOTES |
*
This work was supported by the National Health and Medical
Research Council of Australia and by the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of a Melbourne Research Scholarship (University of Melbourne).
§
Recipient of an NHMRC Peter Doherty postdoctoral award.
¶
Recipient of an Australian Postgraduate Research Award.
International Research Scholar of the Howard Hughes Medical Institute.
**
Recipient of an NHMRC Howard Florey postdoctoral award.

International Research Scholar of the Howard Hughes Medical
Institute. To whom all correspondence should be addressed: The Walter
and Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, VIC 3050, Australia. Tel.: 61-3-9345-2555; Fax:
61-3-9347-0852; E-mail: crabb@wehi.edu.au.
Published, JBC Papers in Press, September 11, 2002, DOI 10.1074/jbc.M206974200
2
W. B. Li and T. Horii, submitted
for publication.
3
M. Delorenzi, unpublished results.
4
M. J. Buckley (2000) CSIRO Mathematical and
Information Services, New South Wales, Australia (available on the
World Wide Web at www.cmis.csiro.au/iap/spot.htm).
5
M. Delorenzi and B. S. Crabb, unpublished data.
6
R. Good and A. Cowman, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
SERA, serine repeat
antigen;
SERP, serine stretch protein;
RT-PCR, reverse
transcriptase-PCR;
GST, glutathione S-transferase;
KAHRP, knob-associated histidine-rich protein.
 |
REFERENCES |
| 1.
|
Delplace, P.,
Fortier, B.,
Tronchin, G.,
Dubremetz, J. F.,
and Vernes, A.
(1987)
Mol. Biochem. Parasitol.
23,
193-201[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Knapp, B.,
Hundt, E.,
Nau, U.,
and Kupper, H. A.
(1989)
Mol. Biochem. Parasitol.
32,
73-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Li, W. B.,
Bzik, D. J.,
Horii, T.,
and Inselburg, J.
(1989)
Mol. Biochem. Parasitol.
33,
13-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Bzik, D. J., Li, W. B.,
Horii, T.,
and Inselburg, J.
(1988)
Mol. Biochem. Parasitol.
30,
279-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Delplace, P.,
Bhatia, A.,
Cagnard, M.,
Camus, D.,
Colombet, G.,
Debrabant, A.,
Dubremetz, J. F.,
Dubreuil, N.,
Prensier, G.,
Fortier, B.,
Hao, A.,
Weber, J.,
and Vernes, A.
(1988)
Biol. Cell
64,
215-221[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Eakin, A. E.,
Higaki, J. N.,
McKerrow, J. H.,
and Craik, C. S.
(1989)
Nature
342,
132[Medline]
[Order article via Infotrieve]
|
| 7.
|
Higgins, D. G.,
McConnell, D. J.,
and Sharp, P. M.
(1989)
Nature
340,
604[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Lyon, J. A.,
Thomas, A. W.,
Hall, T.,
and Chulay, J. D.
(1989)
Mol. Biochem. Parasitol.
36,
77-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Mottram, J. C.,
North, M. J.,
Barry, J. D.,
and Coombs, G. H.
(1989)
FEBS Lett.
258,
211-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Fox, B. A.,
and Bzik, D. J.
(1994)
Mol. Biochem. Parasitol.
68,
133-144[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Debrabant, A.,
Maes, P.,
Delplace, P.,
Dubremetz, J. F.,
Tartar, A.,
and Camus, D.
(1992)
Mol. Biochem. Parasitol.
53,
89-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Debrabant, A.,
and Delplace, P.
(1989)
Mol. Biochem. Parasitol.
33,
151-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Li, J.,
Matsuoka, H.,
Mitamura, T.,
and Horii, T.
(2002)
Mol. Biochem. Parasitol.
120,
177-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Pang, X. L.,
Mitamura, T.,
and Horii, T.
(1999)
Infect. Immun.
67,
1821-1827[Abstract/Free Full Text]
|
| 15.
|
Anders, R. F.,
and Saul, A.
(2000)
Parasitol. Today
16,
444-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Sugiyama, T.,
Suzue, K.,
Okamoto, M.,
Inselburg, J.,
Tai, K.,
and Horii, T.
(1996)
Vaccine
14,
1069-1076[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Fox, B. A.,
Xing-Li, P.,
Suzue, K.,
Horii, T.,
and Bzik, D. J.
(1997)
Exp. Parasitol.
85,
121-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Pang, X. L.,
and Horii, T.
(1998)
Vaccine
16,
1299-1305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Inselburg, J.,
Bzik, D. J., Li, W. B.,
Green, K. M.,
Kansopon, J.,
Hahm, B. K.,
Bathurst, I. C.,
Barr, P. J.,
and Rossan, R. N.
(1991)
Infect. Immun.
59,
1247-1250[Abstract/Free Full Text]
|
| 20.
|
Inselburg, J.,
Bathurst, I. C.,
Kansopon, J.,
Barchfeld, G. L.,
Barr, P. J.,
and Rossan, R. N.
(1993)
Infect. Immun.
61,
2041-2047[Abstract/Free Full Text]
|
| 21.
|
Inselburg, J.,
Bathurst, I. C.,
Kansopon, J.,
Barr, P. J.,
and Rossan, R.
(1993)
Infect. Immun.
61,
2048-2052[Abstract/Free Full Text]
|
| 22.
|
Suzue, K.,
Ito, M.,
Matsumoto, Y.,
Tanioka, Y.,
and Horii, T.
(1997)
Parasitol. Int.
46,
17-25
|
| 23.
|
Knapp, B.,
Nau, U.,
Hundt, E.,
and Kupper, H. A.
(1991)
Mol. Biochem. Parasitol.
44,
1-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Gardner, M. J.,
Tettelin, H.,
Carucci, D. J.,
Cummings, L. M.,
Aravind, L.,
Koonin, E. V.,
Shallom, S.,
Mason, T., Yu, K.,
Fujii, C.,
Pederson, J.,
Shen, K.,
Jing, J.,
Aston, C.,
Lai, Z.,
Schwartz, D. C.,
Pertea, M.,
Salzberg, S.,
Zhou, L.,
Sutton, G. G.,
Clayton, R.,
White, O.,
Smith, H. O.,
Fraser, C. M.,
Hoffman, S. L.,
et al..
(1998)
Science
282,
1126-1132[Abstract/Free Full Text]
|
| 25.
|
Kiefer, M. C.,
Crawford, K. A.,
Boley, L. J.,
Landsberg, K. E.,
Gibson, H. L.,
Kaslow, D. C.,
and Barr, P. J.
(1996)
Mol. Biochem. Parasitol.
78,
55-65[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Gor, D. O., Li, A. C.,
and Rosenthal, P. J.
(1998)
Vaccine
16,
1193-1202[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Trager, W.,
and Jensen, J. B.
(1976)
Science
193,
673-675[Abstract/Free Full Text]
|
| 28.
|
Lambros, C.,
and Vanderberg, J. P.
(1979)
J. Parasitol.
65,
418-420[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Fernandez, V.,
Treutiger, C. J.,
Nash, G. B.,
and Wahlgren, M.
(1998)
Infect. Immun.
66,
2969-2975[Abstract/Free Full Text]
|
| 30.
|
Crabb, B. S.,
and Cowman, A. F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7289-7294[Abstract/Free Full Text]
|
| 31.
|
Fidock, D. A.,
and Wellems, T. E.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10931-10936[Abstract/Free Full Text]
|
| 32.
|
Thompson, J. D.,
Higgins, D. G.,
and Gibson, T. J.
(1994)
Nucleic Acids Res.
22,
4673-4680[Abstract/Free Full Text]
|
| 33.
|
O'Donnell, R. A.,
Saul, A.,
Cowman, A. F.,
and Crabb, B. S.
(2000)
Nat. Med.
6,
91-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Coppel, R. L.,
Bianco, A. E.,
Culvenor, J. G.,
Crewther, P. E.,
Brown, G. V.,
Anders, R. F.,
and Kemp, D. J.
(1987)
Mol. Biochem. Parasitol.
25,
73-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Sambrook, J., Fritsch, E. F., and Maniatis, T.
(eds)
(1989)
Molecular Cloning: A Laboratory Manual
, pp. 9.38-9.40, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 36.
|
Smith, D. B.,
and Johnson, K. S.
(1988)
Gene (Amst.)
67,
31-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
O'Donnell, R. A.,
de Koning-Ward, T. F.,
Burt, R. A.,
Bockarie, M.,
Reeder, J. C.,
Cowman, A. F.,
and Crabb, B. S.
(2001)
J. Exp. Med.
193,
1403-1412[Abstract/Free Full Text]
|
| 38.
|
Knapp, B.,
Hundt, E.,
Enders, B.,
and Kupper, H. A.
(1991)
Behring Inst. Mitt.
88,
147-156
|
| 39.
|
Marshall, V. M.,
Tieqiao, W.,
and Coppel, R. L.
(1998)
Mol. Biochem. Parasitol.
94,
13-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Barr, P. J.,
Inselburg, J.,
Green, K. M.,
Kansopon, J.,
Hahm, B. K.,
Gibson, H. L.,
Lee-Ng, C. T.,
Bzik, D. J., Li, W. B.,
and Bathurst, I. C.
(1991)
Mol. Biochem. Parasitol.
45,
159-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Okech, B. A.,
Nalunkuma, A.,
Okello, D.,
Pang, X. L.,
Suzue, K., Li, J.,
Horii, T.,
and Egwang, T. G.
(2001)
Am. J. Trop. Med. Hyg.
65,
912-917[Abstract]
|
| 42.
|
Wu, Y.,
Kirkman, L. A.,
and Wellems, T. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1130-1134[Abstract/Free Full Text]
|
| 43.
|
Crabb, B. S.,
Cooke, B. M.,
Reeder, J. C.,
Waller, R. F.,
Caruana, S. R.,
Davern, K. M.,
Wickham, M. E.,
Brown, G. V.,
Coppel, R. L.,
and Cowman, A. F.
(1997)
Cell
89,
287-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Reed, M. B.,
Saliba, K. J.,
Caruana, S. R.,
Kirk, K.,
and Cowman, A. F.
(2000)
Nature
403,
906-909 |